Publication: Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas
Issued Date
2014-07-01
Resource Type
ISSN
18733476
03785173
03785173
Other identifier(s)
2-s2.0-84899424141
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
International Journal of Pharmaceutics. Vol.468, No.1-2 (2014), 55-63
Suggested Citation
Alexandra Gaubert, Tina Kauss, Mathieu Marchivie, Boubakar B. Ba, Martine Lembege, Fawaz Fawaz, Jean Michel Boiron, Xavier Lafarge, Niklas Lindegardh, Jean Louis Fabre, Nicholas J. White, Piero L. Olliaro, Pascal Millet, Karen Gaudin Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas. International Journal of Pharmaceutics. Vol.468, No.1-2 (2014), 55-63. doi:10.1016/j.ijpharm.2014.04.023 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/34901
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Preliminary pharmaceutical development of antimalarial-antibiotic cotherapy as a pre-referral paediatric treatment of fever in malaria endemic areas
Other Contributor(s)
Developpements Analytiques et Pharmaceutiques Appliques aux Maladies Negligees et Aux Contrefacons
Universite de Bordeaux
Etablissement Francais du Sang
Mahidol University
OTECI (Office Technique d'Etude et de Coopération Internationale)
Nuffield Department of Clinical Medicine
Organisation Mondiale de la Sante
Universite de Bordeaux
Etablissement Francais du Sang
Mahidol University
OTECI (Office Technique d'Etude et de Coopération Internationale)
Nuffield Department of Clinical Medicine
Organisation Mondiale de la Sante
Abstract
Artemether (AM) plus azithromycin (AZ) rectal co-formulations were studied to provide pre-referral treatment for children with severe febrile illnesses in malaria-endemic areas. The target profile required that such product should be cheap, easy to administer by non-medically qualified persons, rapidly effective against both malaria and bacterial infections. Analytical and pharmacotechnical development, followed by in vitro and in vivo evaluation, were conducted for various AMAZ coformulations. Of the formulations tested, stability was highest for dry solid forms and bioavailability for hard gelatin capsules; AM release from AMAZ rectodispersible tablet was suboptimal due to a modification of its micro-crystalline structure. © 2014 The Authors.